Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9623360 | 0.79 | CHRM5 (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL600653 | 0.74 | ADH1B (0.31) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL1795363 | 0.74 | ADH1B (0.31) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL246739 | 0.74 | INPP5A (0.52) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL6240484 | 0.74 | ALDH1A1 (0.35) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL1795365 | 0.74 | CA2 (0.37) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL92880 | 0.72 | CYP1A2 (0.37) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL16510242 | 0.72 | ADH1B (0.34) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL21602919 | 0.72 | CA2 (0.41) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL965016 | 0.72 | ADH1B (0.34) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158638-B2 | Pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2065388-B1 | PYRAZOLOPYRIMIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2011-09-07 | — | — | EP | disclosed |
| US-20100113410-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2065388-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113410-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | HSP90AB1, HSP90B1, HSP90AA1 | ADH1B 3956/4885ADH1C 2689/4885ADH1A 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.